Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00182000
Status:
COMPLETED
Last Update Posted:
2012-07-16
First Post:
2005-09-13
Brief Title:
Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Medication Trial With D-Cycloserine for Individuals With OCD Currently Receiving Behavior Therapy
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the effectiveness of Seromycin D-cycloserine in enhancing the positive effects of behavior therapy for people with Obsessive-Compulsive Disorder OCD
Detailed Description:
We hope to enroll 50 subjects in a double-blind placebo-controlled study of D-cycloserine augmentation of behavior therapy for Obsessive-Compulsive Disorder All subjects will undergo a pre-treatment assessment and then be randomly assigned to receive Seromycin 100 mg or placebo one-hour before each of 10 therapy sessions Subjects will then come in for a treatment planning session and the behavior therapy sessions delivered twice weekly for 5 weeks Comprehensive assessments of obsessive-compulsive symptoms mood state and cognitions will be given at baseline after 5 treatment sessions after 10 sessions and 1 month and 6 months post-treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None